Phathom Pharmaceuticals, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
PHAT Nasdaq 2830 www.phathompharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE) - Jun 23rd, 2026 5:59 am
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences - May 22nd, 2026 6:00 am
Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting - May 20th, 2026 6:00 am
Phathom Pharmaceuticals (PHAT) Is Up 11.0% After Narrowing Q1 Loss And Reaffirming 2026 Profitability Timeline - May 5th, 2026 4:12 am
How The Phathom Pharmaceuticals (PHAT) Narrative Is Shifting Around Profitability And Exclusivity Risks - May 3rd, 2026 4:08 am
Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual Meeting - May 1st, 2026 6:00 am
Phathom Pharmaceuticals Q1 Earnings Call Highlights - Apr 30th, 2026 7:41 pm
Phathom Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - Apr 30th, 2026 6:48 pm
Phathom (PHAT) Q1 2026 Earnings Transcript - Apr 30th, 2026 3:16 pm
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Tops Revenue Estimates - Apr 30th, 2026 6:30 am
Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update - Apr 30th, 2026 4:59 am
Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026 - Apr 20th, 2026 6:00 am
Assessing Phathom Pharmaceuticals (PHAT) Valuation After Strong One Year Shareholder Return - Apr 16th, 2026 10:29 pm
Eosinophilic Esophagitis Market in the US to Grow at 13.2% CAGR During the Forecast Period (2026–2036) Owing to the Emergence of Drug Classes Such as TSLP Inhibitors, Glucocorticoid Receptor Agonists, and Immunomodulators | DelveInsight - Apr 13th, 2026 11:00 am
Phathom Pharmaceuticals Upgraded by Barclays to Overweight With $18 Target - Mar 27th, 2026 9:07 am
Ocugen Falls as Gene Therapy for Eye Disease Lags in Phase II Study - Mar 25th, 2026 10:15 am
ImmunityBio Rises on China Nod to Bladder Cancer Combo Therapy - Mar 24th, 2026 10:44 am
Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why - Mar 18th, 2026 9:28 am
Mirum Completes Enrollment in Late-Stage EXPAND Study of Livmarli - Mar 17th, 2026 9:39 am
COGT Rise as FDA Accepts Bezuclastinib NDA in Non-Advanced SM - Mar 17th, 2026 9:38 am